These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11080038)

  • 1. Cyclic 3',5'-nucleotide phosphodiesterases: potential targets for anticancer therapy.
    Marko D; Pahlke G; Merz KH; Eisenbrand G
    Chem Res Toxicol; 2000 Oct; 13(10):944-8. PubMed ID: 11080038
    [No Abstract]   [Full Text] [Related]  

  • 2. PDE IV as a target for anti-asthmatic therapy.
    O'Brien C
    Mol Med Today; 1997 Sep; 3(9):368-9. PubMed ID: 9302684
    [No Abstract]   [Full Text] [Related]  

  • 3. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family.
    Shakur Y; Holst LS; Landstrom TR; Movsesian M; Degerman E; Manganiello V
    Prog Nucleic Acid Res Mol Biol; 2001; 66():241-77. PubMed ID: 11051766
    [No Abstract]   [Full Text] [Related]  

  • 4. Searching for cellular targets of novel pteridines downstream of cAMP PDE inhibition.
    Vatter S; Merz KH; Eisenbrand G
    Int J Clin Pharmacol Ther; 2005 Dec; 43(12):607-8. PubMed ID: 16372537
    [No Abstract]   [Full Text] [Related]  

  • 5. Phosphodiesterase 4 regulation of cyclic AMP in pulmonary remodelling: potential roles for isoform selective inhibitors.
    Shepherd MC
    Pulm Pharmacol Ther; 2006; 19(1):24-31. PubMed ID: 16046159
    [No Abstract]   [Full Text] [Related]  

  • 6. Cyclic nucleotide phosphodiesterases: critical modulators of endocrine, metabolic, and cardiovascular function and appealing therapeutic targets.
    Manganiello V
    Curr Opin Pharmacol; 2011 Dec; 11(6):646-8. PubMed ID: 22079477
    [No Abstract]   [Full Text] [Related]  

  • 7. Basic and clinical characteristics of PDE 3 inhibitors as cardiotonic agents.
    Endoh M
    Cardiovasc Drugs Ther; 2007 Jun; 21(3):135-9. PubMed ID: 17508272
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA
    Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
    [No Abstract]   [Full Text] [Related]  

  • 9. Cyclic nucleotide phosphodiesterases of human and rat gastric mucosa.
    Klotz U; Antonin KH; Bieck P
    Naunyn Schmiedebergs Arch Pharmacol; 1977 Jan; 296(2):187-90. PubMed ID: 189231
    [No Abstract]   [Full Text] [Related]  

  • 10. Cyclic nucleotide phosphodiesterase activity of Medicago sativa L.
    Robinson PS; Cooke CJ; Newton RP; Walton TJ; Smith CJ
    Biochem Soc Trans; 1992 Nov; 20(4):355S. PubMed ID: 1336739
    [No Abstract]   [Full Text] [Related]  

  • 11. [Modern representations of multiple forms of cyclic nucleotide phosphodiesterases in mammalian tissues].
    Medvedeva MV
    Biokhimiia; 1995 Mar; 60(3):364-86. PubMed ID: 7734612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic GMP-hydrolyzing phosphodiesterases.
    Francis SH; Corbin JD; Bischoff E
    Handb Exp Pharmacol; 2009; (191):367-408. PubMed ID: 19089337
    [No Abstract]   [Full Text] [Related]  

  • 13. New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors.
    Devillers I; Pevet I; Jacobelli H; Durand C; Fasquelle V; Puaud J; Gaudillière B; Idrissi M; Moreau F; Wrigglesworth R
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3303-6. PubMed ID: 15149695
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclic nucleotide phosphodiesterases (PDE) 3 and 4 in normal, malignant, and HTLV-I transformed human lymphocytes.
    Ekholm D; Mulloy JC; Gao G; Degerman E; Franchini G; Manganiello VC
    Biochem Pharmacol; 1999 Sep; 58(6):935-50. PubMed ID: 10509746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of prostaglandin E2 on two different preparations of cyclic 3',5'-nucleotide phosphodiesterase.
    Egg D; Gantner G
    Pharmacol Res Commun; 1978 Jul; 10(7):609-17. PubMed ID: 213791
    [No Abstract]   [Full Text] [Related]  

  • 16. Cyclic nucleotide phosphodiesterase activities of the embryonic chick ovary.
    Teng CT; Buchler B; Teng CS
    Gen Comp Endocrinol; 1981 Aug; 44(4):409-17. PubMed ID: 6167486
    [No Abstract]   [Full Text] [Related]  

  • 17. Disordered cyclic nucleotide metabolism--a basic defect in atopic dermatitis.
    Butler JM
    Australas J Dermatol; 1984 Apr; 25(1):3-7. PubMed ID: 6205650
    [No Abstract]   [Full Text] [Related]  

  • 18. Cytochemical distribution of cyclic AMP-dependent 3',5'-nucleotide phosphodiesterase in the rat myocardium.
    Okruhlicová L; Tribulová N; Eckly A; Lugnier C; Slezák J
    Histochem J; 1996 Mar; 28(3):165-72. PubMed ID: 8735283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.
    Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Ferlenga P; Pradella L
    Bioorg Med Chem Lett; 2001 Jan; 11(1):33-7. PubMed ID: 11140727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclic nucleotide phosphodiesterase families in intracellular signaling and diabetes.
    Lugnier C
    Adv Exp Med Biol; 2001; 498():253-61. PubMed ID: 11900376
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.